Literature DB >> 9888402

Comparison of a 1.0 molar and a 0.5 molar formulation of gadobutrol in dynamic MR imaging of the liver in rats with hepatocellular carcinoma.

J Kawai1, M Takahashi, N Kato, K Takashima, T Miyazawa.   

Abstract

The efficacy of a 1.0 molar formulation of gadobutrol was compared with that of a 0.5 molar formulation in dynamic magnetic resonance (MR) imaging of the liver in rats with hepatocellular carcinoma (HCC). Seven nodules histologically identified as moderately differentiated HCC underwent dynamic study. In the normal parenchyma surrounding these tumors, the 0.5 molar and 1.0 molar formulations yielded similar enhancement patterns, with maximum enhancement value of approximately 35% at 20 to 40 s after injection. In the tumors, the 0.5 molar formulation induced approximately 65% enhancement, whereas the 1.0 molar formulation, used at the same dose as the 0.5 molar formulation, induced significantly higher enhancement until 10 min after injection with maximum enhancement of approximately 90%. These findings indicate that the 1.0 molar formulation could be more efficacious than the 0.5 molar formulation in dynamic MR studies of moderately differentiated HCC even when injected at the same dose.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888402     DOI: 10.1016/s0730-725x(98)00144-1

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  2 in total

1.  Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas.

Authors:  Young Kon Kim; Young Hwan Lee; Chong Soo Kim; Young Min Han; Seung Bae Hwang
Journal:  Eur Radiol       Date:  2007-04-03       Impact factor: 5.315

2.  Assessment of the hepatic tumor extracellular matrix using elastin-specific molecular magnetic resonance imaging in an experimental rabbit cancer model.

Authors:  Sarah Keller; Tabea Borde; Julia Brangsch; Carolin Reimann; Avan Kader; Daniel Schulze; Rebecca Buchholz; Jan O Kaufmann; Uwe Karst; Eyk Schellenberger; Bernd Hamm; Marcus R Makowski
Journal:  Sci Rep       Date:  2020-11-27       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.